Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $83.64 Consensus Price Target from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $82.57.

A number of research analysts have recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, July 14th. William Blair began coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price target for the company. Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday, July 14th. HC Wainwright upgraded Ultragenyx Pharmaceutical to a “buy” rating and set a $80.00 target price on the stock in a research report on Monday. Finally, Wells Fargo & Company lowered their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, July 10th.

Ultragenyx Pharmaceutical Trading Down 1.9%

Shares of RARE opened at $27.14 on Monday. The stock’s 50-day moving average price is $34.29 and its two-hundred day moving average price is $37.40. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $60.37. The company has a market capitalization of $2.57 billion, a PE ratio of -4.62 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. The company had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. During the same quarter last year, the business earned ($2.03) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 28.0% compared to the same quarter last year. Equities research analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company’s stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company’s stock, valued at $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its holdings in shares of Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock valued at $3,284,000 after buying an additional 268 shares during the last quarter. GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 323 shares in the last quarter. Xponance Inc. boosted its stake in Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company’s stock valued at $455,000 after purchasing an additional 347 shares during the last quarter. BOKF NA increased its holdings in Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 382 shares in the last quarter. Finally, Oak Ridge Investments LLC increased its holdings in Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company’s stock worth $643,000 after purchasing an additional 395 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.